Other

University of Iowa Research Foundation

Coley Pharmaceutical Group, Inc.

Coley Pharmaceutical Gmbh

Pfizer Corporation

Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Ottawa Hospital Research Institute

Ottawa Health Research Institute

Zoetis Belgium S.a

Loeb Health Research Institute at the Ottawa Hospital

Ottawa Civic Hospital Loeb Research

Université D'ottawa

University of Ottawa

Pfizer Vaccines, Lcc

Heather Lynn Davis

Arthur Mertz Krieg

Joachim Schorr

Risini Dhammika Weeratna

Marie-Louise Michel

Robert Gerald Whalen

Tong Wu

Michael J McCluskie

Alan Daniel Brown

Paul Joseph Dominowski

Jörg Vollmer

Lyn Howard Jones

David Cameron Pryde

James Richard Merson

Erin Kristen Parsons

Henrik Carl Schonheyder

Schorr Joachim

Susan M Efler

Navneet K Ahluwalia

Nicolai Lohse

Lars Ostergaard

Nickolas Anastasiou

Keshab Bhattacharya

Parag Ashok Kolhe

Paul Robert Mehelic

Jennifer Marie Thorn

David R Stead

David P Gervais

Ole Schmeltz Sogaard

Jari Ilmari Finneman

David Robert Stead

Robert Gérald Whalen

Michael John Mccluskie

Described are vaccines having one or more antigens cholesterol and CpG. Aspects of the invention relate to the use of the vaccines of the invention for the treatment and/or prevention of human and animal disorders.

Vaccines comprising cholesterol and CpG as sole adjuvant-carrier molecules

The invention relates to immunostimulatory oligonucleotides and methods of using immunostimulatory oligonucleotides to induce an antigen-specific immune response. The invention further relates to a vaccine that comprises an immunostimulatory oligonucleotide and an antigen, and comprises a pharmaceutically acceptable carrier. The immunostimulatory oligonucleotides of the invention, in some embodiments, include one or more modified linkage(s).

Immunostimulatory oligonucleotides

The present invention relates to new pneumococcal vaccines. The invention also relates to vaccination of subjects, in particular immunocompromised subjects, against pneumoccocal infections using said novel pneumococcal vaccines.

Pneumococcal vaccine and uses thereof

The present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (III): wherein m, n, W, -(spacer)-, X* and Y are as defined in the description. In certain embodiments, said nicotine-derived hapten-carrier conjugates can be used to prepare vaccines for the treatment and/or prevention of nicotine addiction.

Conjugates for the prevention or treatment of nicotine addiction

The invention relates methods and products for inducing mucosal immunity. In particular, the invention relates to the use of immunostimulatory oligonucleotides containing a CpG motif for inducing mucosal immunity. The CpG immunostimulatory oligonucleotides may be administered alone or in combination with antigen and/or with other adjuvants.

Methods and products for inducing mucosal immunity

The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.

Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant

The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, the subjects are those that are non-responsive to non-CpG therapy. Preferably, the subjects are treated with C class CpG immunostimulatory nucleic acids having a semi-soft backbone.

Methods and products related to treatment and prevention of hepatitis C virus infection

Nucleotide vector comprising at least one gene or one complementary DNA coding for at least a portion of a virus, and a promoter providing for the expression of such gene in muscle cells. The gene may be the S gene of the hepatitis B virus. A vaccine preparation containing said bare DNA is injected into the host previously treated with a substance capable of inducing a coagulating necrosis of the muscle fibres.

Nucleotide vector vaccine for immunization against hepatitis

Method of inducing an antigen-specific immune response by administering a synergistic combination of adjuvants comprising unmethylated CpG-containing nucleic acids and a non-nucleic acid adjuvant

The present invention shows that DNA vaccine vectors can be improved by removal of CpG-N motifs and optional addition of CpG-S motifs. In addition, for high and long-lasting levels of expression, the optimized vector should include a promoter/enhancer that is not down-regulated by the cytokines induced by the immunostimulatory CpG motifs. Vectors and methods of use for immununostimulation are provided herein. The invention also provides improved gene therapy vectors by determining the CpG-N and CpG-S motifs present in the construct, removing stimulatory CpG (CpG-S) motifs and/or inserting neutralizing CpG (CpG-N) motifs, thereby producing a nucleic acid construct providing enhanced expression of the therapeutic polypeptide. Methods of use for such vectors are also included herein.

Vectors and methods for immunization or therapeutic protocols

The invention relates to methods of inducing an immunogenic response in a subject that include administering a nucleotide plasmid vector that includes a gene coding for a surface antigen protein derived from hepatitis B virus and a promoter for the expression of the gene. The invention also relates to vaccine compositions for protecting against hepatitis B virus.

Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis

The present invention shows that DNA vaccine vectors can be improved by removal of CpG-N motifs and optional addition of CpG-S motifs. In addition, for high and long-lasting levels of expression, the optimized vector should include a promoter/enhancer that is not down-regulated by the cytokines induced by the immunostimulatory CpG motifs. Vectors and methods of use for immunostimulation are provided herein. The invention also provides improved gene therapy vectors by determining the CpG-N and CpG-S motifs present in the construct, removing stimulatory CpG (CpG-S) motifs and/or inserting neutralizing CpG (CpG-N) motifs, thereby producing a nucleic acid construct providing enhanced expression of the therapeutic polypeptide. Methods of use for such vectors are also included herein.

The present invention relates to methods of immunization of aquaculture species by introducing DNA expression systems into the aquaculture species. Such DNA expression systems preferably include DNA sequences encoding polypeptides of pathogens of species of aquaculture. The present invention also relates to methods of administration of DNA expression systems into aquaculture. Such methods include injection, spray, and immersion techniques. The methods of this invention are useful for prophylactic vaccination or therapeutic immunization of fin-fish, shellfish, or other aquatic animals against infectious diseases.

DNA based vaccination of fish

Growing community of inventors

Ottawa, Canada

Heather Lynn Davis